In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $185.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sean Laaman has given his Buy rating due to a combination of factors that highlight Jazz Pharmaceuticals’ strategic positioning and growth potential. The company reported strong performance in its neuro product segment, particularly with the launches of Modeyso and Zepzelca, which have shown promising sales and market acceptance. Additionally, Jazz has made significant progress in its zanidatamab Phase 3 GEA PFS analysis, ensuring robust data maturity and statistical power, which could enhance its competitive edge.
Despite the anticipated entry of generic Xyrem in 2026, Jazz is focused on maintaining the differentiated position of Xywav, emphasizing its unique low-sodium formulation and FDA approval for IH treatment. The company is also actively working with payers to secure patient access, which could mitigate potential revenue disruptions. Furthermore, the recent FDA approval of Zepzelca as a first-line maintenance therapy for extensive-stage small cell lung cancer, along with its inclusion in NCCN guidelines, is expected to drive sales growth. These strategic initiatives and product developments underpin Sean Laaman’s optimistic outlook on Jazz Pharmaceuticals’ future performance.
In another report released today, TD Cowen also reiterated a Buy rating on the stock with a $205.00 price target.